Welcome to CHARTER as a Resource
The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study was first funded in September 2002 in response to NIMH RFA 00-AI-0005 to explore the changing presentation of HIV neurological complications in the context of emerging antiviral treatments such as highly active antiretroviral therapy (HAART). Current public funding includes grants from the National Institute of Health (NIH), the National Institute of Mental Health (NIMH) and the National Institute of Neurological Disorders and Stroke (NINDS) via the CHARTER Extension (NIMH/NINDS Award Number HHS-N-271-2010-00036C) and CHARTER As A Resource (NIH/NIMH/NINDS Award Number HHSN271201000030C).
CHARTER’s study aims are to determine how central and peripheral nervous system complications of HIV are affected by different histories and regimens of antiretroviral therapy (ART). Participants receive comprehensive neuromedical, neurocognitive, and laboratory examinations, with a subset undergoing host/viral genetic characterization and neuroimaging. In order to have a broad representation of participant characteristics, CHARTER is conducted at six performance sites nationally whose activities are coordinated by UCSD, the principal grantee institution, which includes several technical, scientific, and administrative cores to guide the work.